Bergen – 17 November 2005: – The Board of Directors of NorDiag ASA on 16 November 2005 resolved to propose a share issue of up to 7,500,000 shares. Together with the financial advisors the Board has proposed a price range from NOK 9.50 to NOK 11 per share in connection with the share issue and the planned listing of the company’s shares on Oslo Børs.

The final price will be set after the end of the subscription period, which is proposed to run from 21 November until 2 December, after a book-building process. In connection with the share issue and the listing on Oslo Børs, the company will prepare a prospectus which will be reviewed by Oslo Børs.

The Board of NorDiag ASA applied for a listing on Oslo Børs on 2 November 2005.

Pareto Securities ASA, Pareto Private Equity ASA and Handelsbanken Capital Markets will act as Managers in connection with the share issue and the listing.

For further information, please contact:
Christian Horn, CEO, NorDiag ASA, +47 90 16 31 53

About NorDiag ASA
NorDiag is a biotechnology company focusing on early diagnosis of cancer. The company’s first product is Genefec for genetic diagnosis of colorectal cancer. The test yields positive results if the patient has mutations in the genes Ki-Ras of p53, which means that a tumour is under development.